Olfax Medical
Olfax Medical is a clinical-stage biopharmaceutical company specializing in the development of nasally administered therapeutics for trigeminal-mediated pain. The company leverages direct-to-nerve drug delivery to target headache disorders such as cluster headache, migraine, post-traumatic headache, and trigeminal neuralgia. Their primary focus is on translating the sphenopalatine ganglion block procedure into a self-administered treatment that bypasses systemic circulation, aiming for rapid pain relief with fewer side effects.
Industries
N/A
Olfax Medical
16 Biltmore Avenue, Suite 300, Asheville, NC 28803
Olfax Medical is currently seeking investment
Olfax Medical is seeking a series-a investment in the range of 5m-20m
Products
A self-administered, investigational intranasal combination product in clinical development for the rapid treatment of cluster headache, refractory migraine, and other trigeminal-mediated pain conditions.
A self-administered, investigational intranasal combination product in clinical development for the rapid treatment of cluster headache, refractory migraine, and other trigeminal-mediated pain conditions.
Expertise Areas
- Neurotherapeutic drug development
- Intranasal drug delivery
- Headache disorder therapeutics
- Combination drug-device products
Key Technologies
- Intranasal combination drug-device platforms
- Direct-to-nerve delivery systems
- Sphenopalatine ganglion block translation
- Self-administered therapeutics
Key People
Senior Advisor
Clinical Development / Medical Affairs
Nonclinical and Early Clinical Development
Regulatory Affairs
Senior Advisor
Clinical Development / Medical Affairs
Nonclinical and Early Clinical Development
Regulatory Affairs
News & Updates
Recognized as a leading life science startup in North Carolina at the 2022 NC BIONEER Venture Challenge.
Awarded $54,000 grant from the NIH-funded DRIVEN Accelerator Hub supporting migraine therapy technology.
Olfax Medical received a $5.6 million award from the US Department of Defense’s Peer Reviewed Medical Research Program (PRMRP) to support research and development of rapid, intra-nasal headache treatments.
Received cumulative funding from the North Carolina Department of Commerce to advance development of nasally delivered therapeutics for neurological conditions.
Received a Phase I Small Business Innovation Research (SBIR) grant from NIH/NINDS to develop an acute, non-addictive, at-home nasal headache therapy.
Chosen as one of three companies in the DRIVEN Accelerator Hub’s 2021 Partnership Program for biomedical startup support.
Recognized as a leading life science startup in North Carolina at the 2022 NC BIONEER Venture Challenge.
Awarded $54,000 grant from the NIH-funded DRIVEN Accelerator Hub supporting migraine therapy technology.
Olfax Medical received a $5.6 million award from the US Department of Defense’s Peer Reviewed Medical Research Program (PRMRP) to support research and development of rapid, intra-nasal headache treatments.
Received cumulative funding from the North Carolina Department of Commerce to advance development of nasally delivered therapeutics for neurological conditions.
Received a Phase I Small Business Innovation Research (SBIR) grant from NIH/NINDS to develop an acute, non-addictive, at-home nasal headache therapy.
Chosen as one of three companies in the DRIVEN Accelerator Hub’s 2021 Partnership Program for biomedical startup support.